Michael Egholm - May 22, 2025 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
President & CEO, Director
Signature
/s/ Michael Egholm by Tomone Tanaka, Attorney-in-Fact
Stock symbol
LAB
Transactions as of
May 22, 2025
Transactions value $
-$5,126
Form type
4
Date filed
5/27/2025, 08:28 PM
Previous filing
May 22, 2025
Next filing
May 28, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Egholm Michael President & CEO, Director C/O STANDARD BIOTOOLS INC., 2 TOWER PLACE, STE 2000, SOUTH SAN FRANCISCO /s/ Michael Egholm by Tomone Tanaka, Attorney-in-Fact 2025-05-27 0001559779

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Sale -$5.13K -5.12K -0.19% $1.00 2.75M May 22, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were sold to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on March 21, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission ("SEC") on March 24, 2025.
F2 Represents the weighted average sales price per share. The shares sold at prices ranging from $0.9403 to $1.03 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.